Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Canberk, S (Author) Other; Lima, AR (Author) Other; Pinto, M (Author) Other; Soares, P (Author) FMUP; Maximo, V (Author) FMUP

Journal

Title: Frontiers In Endocrinology

Vol. 12

ISSN: 1664-2392

Publisher: Frontiers Media

Indexing

ISI Web of Knowledge - 4 Citations

Scopus - 5 Citations

Other information

Authenticus ID: P-00V-1GN

DOI: 10.3389/fendo.2021.674666

Abstract (EN): It has been widely described that cancer genomes have frequent alterations to the epigenome, including epigenetic silencing of various tumor suppressor genes with functions in almost all cancer-relevant signalling pathways, such as apoptosis, cell proliferation, cell migration and DNA repair. Epigenetic alterations comprise DNA methylation, histone modification, and microRNAs dysregulated expression and they play a significant role in the differentiation and proliferation properties of TC. In this review, our group assessed the published evidence on the tumorigenic role of epigenomics in Hurthle cell neoplasms (HCN), highlighting the yet limited, heteregeneous and non-validated data preventing its current use in clinical practice, despite the well developed assessment techniques available. The identified evidence gaps call for a joint endeavour by the medical community towards a deeper and more systematic study of HCN, aiming at defining epigenetic markers in early diagnose, allowing for accurate stratification of maligancy and disease risk and for effective systemic treatment.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 12